Exploring the intersection between orthostatic hypotension and daytime sleepiness in Parkinson's disease

Abhimanyu Mahajan, MD, MHS[1], Kevin R. Duque, MD[1], Alok K. Dwivedi, PhD[1,2], Jesus Abanto, MD[1], Luca Marsili, MD, PhD[1], Emily J. Hill, MD[1], Ameya Saraf[1], Kelsey J. McDonald[1], Adebukunola Arowosegbe[1], Heba A. Deraz, MD, MSc, PhD[1,3], Aaron Bloemer, BS[1], Alberto J. Espay, MD, MSc[1]

[1] James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA

[2] Division of Biostatistics & Epidemiology, Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center, El Paso, Texas, USA.

[3] Department of Neurology, Cairo University, Cairo, Egypt

Corresponding author:

Abhimanyu Mahajan, MD, MHS

Gardner Center for Parkinson's Disease and Movement disorders, University of Cincinnati, Cincinnati, OH

Email: abhimanyu.mahajan@uc.edu

Phone: (513) 475-8730

Fax: (513) 475-8033

Word count: 2098

Abstract: 246

References: 24

Tables and Figures: 2

Supplementary data: 1

Key words: Parkinson's disease, daytime sleepiness, orthostatic hypotension, neurogenic orthostatic hypotension, dysautonomia

Study Funding: None

Declaration of interest:

AM reports no relevant financial disclosures or conflicts of interest

KRD reports no relevant financial disclosures or conflicts of interest

AKD reports no relevant financial disclosures or conflicts of interest

JA reports no relevant financial disclosures or conflicts of interest

LM reports no relevant financial disclosures or conflicts of interest

EJH reports no relevant financial disclosures or conflicts of interest

AS reports no relevant financial disclosures or conflicts of interest

KJM reports no relevant financial disclosures or conflicts of interest

AA reports no relevant financial disclosures or conflicts of interest

HAD reports no relevant financial disclosures or conflicts of interest

AB reports no relevant financial disclosures or conflicts of interest

AJE reports no relevant financial disclosures or conflicts of interest

Abstract

Introduction

Daytime sleepiness, reported in about 50% of patients with Parkinson's disease (PD), is associated with high morbidity, poor quality of life and increased risk for accidents. While an association between dysautonomia and daytime sleepiness in early, de-novo PD has been reported, our understanding of the role of medications, cognitive status and disease duration on this relationship is inadequate.

Methods

Data were analyzed from the prospective Cincinnati Cohort Biomarkers Program. The primary outcome of interest was daytime sleepiness, as measured by the Epworth Sleepiness Scale (ESS). The primary exposure variable was orthostatic hypotension (OH) with a sub-analysis for the neurogenic OH (nOH) subtype. Regression analyses were carried out adjusting for the following covariates: age, sex, disease duration, education, comorbidities, anti-cholinergic burden, levodopa equivalent dose (LEDD), motor subscore of the Movement disorder society-unified Parkinson's disease rating scale, Hoehn and Yahr stage (H&Y), Beck Depression Inventory, and Beck Anxiety Inventory.

Results

Data on 456 subjects with PD were analyzed. OH was strongly associated with ESS scores, particularly in those with anticholinergic medication use after adjusting for all covariates (RC, 4.30; p<0.001). This adjusted association was more pronounced in men with early disease duration, early H&Y stage, no cognitive decline, and LEDD≤750 mg. Similar results were noted with nOH.

Conclusions

OH is associated with daytime sleepiness to a greater extent in male patients with early disease and magnified by such prescribing practices as anticholinergic medication use and dopaminergic dosage in early PD. This relationship is independent of cognitive decline.

1. Introduction

Daytime sleepiness, difficulty in maintaining a desired level of wakefulness, is a disabling feature of neurodegenerative disorders[1] and is noted in up to 50% of patients with PD.[2] It is associated with high morbidity, poor quality of life and increased risk for accidents later in the disease.

Orthostatic hypotension (OH), secondary to cardiovascular dysautonomia, is present in approximately 50% of patients with PD. Even if asymptomatic, it may affect overall function and quality of life.[3] On standing, when a drop in blood pressure is not accompanied by a corresponding increase in heart rate, it is referred to as neurogenic OH (nOH), a manifestation of sympathetic denervation in PD. OH has been associated with compromised mentation, with clinical observations suggesting a causal relationship through cerebral hypoperfusion.[4]

In healthy older adults, those with higher systolic blood pressure (BP) levels and diastolic BP variability during waking hours have been noted to have greater daytime sleepiness. Our understanding of this complicated relationship, especially the role of medications, disease duration, and its impact on PD patients is inadequate. We sought to understand the link between these manifestations of PD with the goal of identifying patients at a higher risk to consider ameliorating treatment strategies.

2. Material and methods

2.1 Study Sample

Data was prospectively collected as a part of the Cincinnati Cohort Biomarkers Program (CCBP).[5] The CCBP systematically collects demographic and clinical data, including the use of validated scales, in patients with PD and other neurodegenerative disorders.[5] Consecutive participants with a diagnosis of idiopathic PD[6] and data on the primary exposure were included in this analysis. The study protocol was approved by the University of Cincinnati Institutional Review Board (IRB# 2018–5699).

2.2 Primary outcomes and exposures

Our primary outcome of interest was the Epworth Sleepiness Scale (ESS) score, a validated, self-reported measure of daytime sleepiness in PD.[7, 8] The primary exposure variable was OH, defined by a change in systolic blood pressure (SBP) of ≤ 15 mmHg or diastolic blood pressure (DBP) of ≤ 7 mmHg, as previously validated from the sitting to the standing position[9], which is the protocol for collecting orthostatic vital signs used in the CCBP. In addition, we performed sensitivity analysis by using a cut-off of a change in SBP ≤ 20 or DBP ≤10, the standard lying-to-standing thresholds for OH.[10] Finally, we also used as an exposure neurogenic OH (nOH), defined as a ratio of an increase in heart rate (HR) to a decrease in SBP of <0.5.[11]

2.3 Covariates

Demographic data: age, sex, education, patient-identified race (white or non-white) and ethnicity (non-Hispanic, Hispanic).

Clinical data: diagnosis, disease duration (time since motor symptom onset), Hoehn & Yahr (H&Y) stage, motor subscale of the Movement disorder society Unified Parkinson's Disease Rating Scale (MDS UPDRS III), Montreal Cognitive Assessment (MoCA), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI) and presence/absence of comorbidities, with particular interest in obstructive sleep apnea (OSA), anxiety, depression, cardiovascular disease, chronic kidney disease, cognition impairment, diabetes, and cancer. Anticholinergic burden (ACB) and levodopa equivalent daily dose (LEDD) were extracted or computed from the data.[12, 13]

2.4 Data analysis

All scores and continuous variables were summarized with mean and standard deviation (SD) and non-normal data with median and interquartile range (IQR). Categorical variables were described with frequency and proportion. All baseline characteristics were compared with a t-test/Wilcoxon rank sum test or chi-square test according to OH and nOH status. In the unadjusted analysis, we compared ESS scores between groups using unpaired t-tests. Interactions between baseline characteristics and OH and nOH for ESS outcome measure were also assessed using linear regression models. We performed adjusted analyses using a multiple linear regression model considering OH (or nOH) as the primary exposure variable. All prespecified covariates including age, sex, disease duration, education, number of comorbidities, ACB scores, LEDD, MDS-UPDRS III, H&Y stage, BDI, and BAI scores were adjusted in the final analyses. Log-transformed LEDD, disease duration, MDS-UPDRS III, BDI, and BAI scores were used in the analyses. Considering the skewness in the outcome measures, the adjusted associations were further validated by fractional logit beta regression analyses by converting outcome scores to percentage outcome scores as well as by using log-transformed outcome measures in linear regression analyses. We further summarized the adjusted associations according to pre-specified subgroups based on age groups, sex, LEDD levels, MOCA levels, disease duration groups, anticholinergic medication use, H&Y stage, and MDS-UPDRS III groups using multiple linear regression analyses and confirmed using log-transformed outcome measures. The results of linear regression analyses were described with regression coefficient (RC) while results of beta regression with odds ratio (OR) with 95% confidence interval (CI) and p-value. The results were considered statistically significant at a 5% level of significance. All statistical analyses were conducted using STATA 17.

3. Results

A total of 456 PD subjects with data on the primary exposure variables were analyzed. Their mean age was 67.4 (SD: 9.5) years with a median disease duration of 5.7 (IQR: 3.3, 9.5) years. Nearly 90% of the subjects had H&Y stage <3. The mean MoCA score was 26 (SD: 3.2). Twenty-two percent of patients had OH and 7.5% had nOH. Baseline characteristics between subjects with and without OH/ nOH were similar, except for greater male predominance in the OH cohort (Table 1).

3.1 OH and ESS

There was no difference in mean ESS scores (7.5±5.2 vs. 6.7 ± 4.5, p=0.18) in PD subjects with and without OH. The presence of OH was associated with higher ESS scores (RC 1.4; p=0.007) after adjusting for age, disease duration, sex, education, comorbidities, anticholinergic medication use, LEDD, MDS-UPDRS III, H&Y stage, BAI, BDI, and MoCA score. Male sex (RC 1.3, p=0.006), BDI scores (RC 1.3, p<0.001), BAI scores (RC 0.8, p=0.007) and MoCA scores (RC -0.2, p=0.005) were significantly associated with ESS scores. (Supplementary data) Greater odds of higher ESS scores with OH were noted in adjusted analysis (OR 1.3; p=0.007) . This association remained unchanged with the analysis of log-transformed ESS scores (Supplementary data)

A significant interaction effect of anticholinergic medication use with OH on ESS was observed (Supplementary data). OH was strongly associated with ESS scores, particularly in the subgroup of patients with anticholinergic medication use in both unadjusted (RC, 2.6; p=0.02) and adjusted (RC, 4.3; p<0.001) analyses (Figure 1). In addition, the adjusted association of OH with ESS scores was more pronounced in males with early disease duration, early H&Y stage, no cognitive decline, and LEDD≤750 mg. These associations were confirmed in sensitivity analyses with log-transformed and percentage ESS scores. (Supplementary data).

Additional Sensitivity analyses

Revised OH (cut off of a change in SBP≤20 or DBP≤10 from sitting to standing) remained consistently associated with untransformed, log-transformed scores, and percentage ESS (Supplementary data). The aforementioned relationship between OH and ESS with anticholinergic medication use as an interaction variable was further confirmed with the revised OH criteria. (Figure 1)

3.2 nOH and ESS

Like OH, ESS scores were not significantly different according to nOH status (7.5±5.2 vs. 6.9 ± 4.6, p=0.44) in unadjusted analysis. Higher ESS scores were significantly associated with nOH after adjusting for covariates (RC, 1.6; p=0.046). The association between nOH and ESS scores remained unchanged in sensitivity analyses of transformed ESS scores (Supplementary data). nOH was markedly associated with higher ESS scores in unadjusted (RC, 2.10; p=0.03) and adjusted (RC, 2.62; p=0.005) analyses (Supplementary data; Figure 1). Adjusted association between nOH and ESS scores was more pronounced in male patients with lesser disease duration, and early H&Y stage after accounting for LEDD and other covariates. These conclusions were unchanged in sensitivity analyses using transformed ESS scores (Supplementary data).

4. Discussion

Prior literature on early, untreated disease found no difference between PD and healthy controls in excessive daytime sleepiness. However, a clinical correlation between sleepiness and dysautonomia and mood was reported in PD.[14] Our analysis of data from a clinically representative,[5, 15] robust sample provides insight into multiple aspects of the relationship between OH and daytime sleepiness in PD.

The association of nOH with daytime sleepiness suggests a common underlying neurodegenerative process. This would be consistent with their greater co-prevalence later in the disease and with the known contribution of underlying neurodegeneration to the autonomic system and sleep disruption.[2, 16] The co-prevalence and worsening of daytime sleepiness with nOH highlights the involvement of brainstem and reticular activating system in PD in relatively early (median disease duration: 5.7 years), treated PD. The cholinergic system in PD is important to this discussion. A significant loss of cholinergic neurons in the brainstem have been reported in post-mortem studies of individuals with PD.[17] These neurons innervate rostral and caudal targets including hypothalamic sleep-wake regulating regions. Severity of regional cholinergic neuron loss correlates with PD symptom severity.[18] Our analysis shows a that use of anticholinergic medications enhances the relationship between OH and daytime sleepiness in PD.

Dopamine circuitry is central to the sleep-wake cycle and has been implicated in sleep issues seen in PD and restless leg syndrome.[2] Sleep disturbances and daytime sleepiness are common non-motor features of PD, affecting nearly two-thirds of patients.[2, 19] Dopamine dysfunction in the hypothalamus, a key structure in the regulation of the sleep-wake state, leading to direct/ indirect regulation of the orexinergic neurons has been hypothesized to be the underlying issue behind sleep issues in PD.[2] In our analysis, we found that a relatively low dopamine dose (LEDD ≤750 mg) in a subset of patients (males with early PD, no cognitive impairment) was associated with a stronger relationship between OH and daytime sleepiness. Due to its multi-factorial etiology, daytime sleepiness is often tough to treat[20]. Specific prescribing practices, identified in our analysis offer clinicians a potential avenue for symptomatic improvement with therapeutic adjustment.

The discrepancy between disease severity (89% of sample with H&Y < 3) and manifestations of "advanced" disease (presence of daytime sleepiness/ OH) highlights the importance of multiple factors guiding clinical manifestations of the impact of disease progression. The intersection of daytime sleepiness, orthostatic hypotension and cognition in PD offers an interesting insight into underlying biological mechanisms. Daytime sleepiness is not uncommonly seen in PD patients with cognitive impairment with or without OH. OH is independently associated with cognitive

impairment in PD. Early OH but not its symptom severity appears to increase the risk of dementia by 14% per year in PD.[21] This association is not explained by more widespread Lewy, β-amyloid, tau, Alzheimer, or cerebrovascular pathologies. OH is known to be associated with significantly worse sustained attention, visuospatial and verbal memory in PD, and these findings are not explained by white matter disease burden.[22] Locus coeruleus, implicated in both, noradrenaline release and attention, has also been proposed to explain the relationship between OH and cognitive impairment. Dopaminergic medications have a direct impact on OH in PD It is possible that the reported impact of dopamine replacement on cognition may at least partially be secondary to the effect of OH on daytime sleepiness.[23] Our analysis shows a direct relationship between OH and daytime sleepiness without a contribution from cognitive impairment.

OSA is common in PD and an important cause of daytime sleepiness. Our data showed no difference in the prevalence of OSA between those with and without OH. Another strength of the study includes the use of comprehensive, prospectively collected data with a large sample size for analysis. Our patient population includes substantial representation of urban, suburban, and rural populations. Our analysis utilized established scales for assessment including the ESS, a well-known measure of daytime sleepiness. We conducted sensitivity analysis by utilizing a different cut-off for OH and an established cut-off for nOH, which did not alter our conclusions.

Our study is not without limitations. Our primary exposure is based on a cut-off that is not validated in PD. The assessment of vitals was done in the sitting and standing positions based on feedback of substantial discomfort with the tilt table by multiple subjects with PD in the CCBP program. Recognizing these issues, this approach has been deemed acceptable per recommendations of a consensus panel.[24] We additionally performed analysis using modified, validated cut-offs to mitigate this shortcoming. As our data was cross-sectional in nature, a causal relationship between OH and daytime sleepiness may not be assumed. The absence of a control group is another limitation of this analysis.

5. Conclusions

OH contributes to daytime sleepiness in PD. This relationship is stronger in those on anticholinergic medications, a relatively lower dose of levodopa, and in the subset of cognitively unimpaired PD patients with early disease. The stronger relationship between nOH and daytime sleepiness in early disease (≤ 5 years), may, at least partially, represent a feature of the "malignant" phenotype of PD. Early OH in PD should alert clinicians to the need for careful assessment and care of these manifestations.

6. Acknowledgments

We want to thank all subjects who participated in the CCBP study.

7. Author's contributions

AM: study conception and design, writing of the first draft of the manuscript, editing of final version of the manuscript

KRD: acquisition of data, revising the manuscript for content

AD: study design, data statistics and analysis, revising the manuscript for content

JA: acquisition of data, revising the manuscript for content

LM: acquisition of data, revising the manuscript for content

EJH: acquisition of data, revising the manuscript for content

AS: acquisition of data, revising the manuscript for content

KJM: acquisition of data, revising the manuscript for content

AA: acquisition of data, revising the manuscript for content

HAD: acquisition of data, revising the manuscript for content

AB: acquisition of data, revising the manuscript for content

AJE: study conception, revising the manuscript for content, editing of final version of the manuscript

8. Financial disclosures

AM has received funding from the Parkinson's Foundation, Sunflower Parkinson's disease foundation and Dystonia Medical Research Foundation outside of the submitted work.

KRD reports no financial disclosures

AKD reports no financial disclosures

JA reports no financial disclosures

LM has received honoraria from the International Association of Parkinsonism and Related Disorders (IAPRD) Society for social media and web support, and personal compensation as a consultant/scientific advisory board member for Acadia. Dr. Marsili has received a grant (collaborative research agreement) from the International Parkinson and Movement Disorders Society for the MDS-UTRS Validation Program (Role: PI), Non Profit.

EJH reports no financial disclosures

AS reports no financial disclosures

KM reports no financial disclosures

AA reports no financial disclosures

HAD has been funded by the Parkinson's Foundation/ International Association of Parkinsonism and Related Disorders (IAPRD) outside of the submitted work.

AB reports no financial disclosures

AJE has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acadia, Avion, Acorda, Kyowa Kirin, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Praxis Precision Medicines, Citrus Health, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics and is co-inventor of the patent "Compositions and methods for treatment and/or prophylaxis of proteinopathies."

9. Table and Figure

Table 1. Baseline characteristics of the cohort by presence of orthostatic hypotension and neurogenic orthostatic hypotension

Factor	Entire cohort	non-OH	OH	p-value	non-nOH	nOH	p-value
N	456	356	100		422	34	
Age (years), mean (SD)	67.4 (9.5)	67.7 (9.5)	66.3 (9.5)	0.19	67.3 (9.5)	68.1 (9.0)	0.65
Sex-Male	299 (65.7%)	243 (68.5%)	56 (56.0%)	0.021	275 (65.3%)	24 (70.6%)	0.53
Race-White	439 (96.3%)	343 (96.3%)	96 (96.0%)	0.87	406 (96.2%)	33 (97.1%)	0.80
Ethnicity- Not Hispanic	443 (99.1%)	345 (99.1%)	98 (99.0%)	0.89	410 (99.3%)	33 (97.1%)	0.19
HS education	398 (89.8%)	311 (89.6%)	87 (90.6%)	0.77	367 (89.3%)	31 (96.9%)	0.17
Number of comorbidities				0.45			0.12
0	151 (33.1%)	118 (33.1%)	33 (33.0%)		142 (33.6%)	9 (26.5%)	
1	186 (40.8%)	146 (41.0%)	40 (40.0%)		171 (40.5%)	15 (44.1%)	
2	65 (14.3%)	53 (14.9%)	12 (12.0%)		60 (14.2%)	5 (14.7%)	
3	32 (7.0%)	22 (6.2%)	10 (10.0%)		31 (7.3%)	1 (2.9%)	
4	15 (3.3%)	12 (3.4%)	3 (3.0%)		11 (2.6%)	4 (11.8%)	
5	6 (1.3%)	5 (1.4%)	1 (1.0%)		6 (1.4%)	0 (0.0%)	
6	1 (0.2%)	0 (0.0%)	1 (1.0%)		1 (0.2%)	0 (0.0%)	
ACB score, mean (SD)	0.6 (1.2)	0.6 (1.2)	0.7 (1.4)	0.28	0.6 (1.2)	0.4 (1)	0.35
LEDD, median (IQR)	750.0 (400.0, 1100.0)	750.0 (400.0, 1075.0)	787.5 (400.0, 1200.0)	0.40	750.0 (413.8, 1100.0)	800.0(300.0, 1350.0)	0.73
Disease duration in years, median (IQR)	5.7 (3.3, 9.5)	5.9 (3.3, 9.5)	5.4 (3.3, 9.3)	0.56	5.8 (3.3, 9.5)	5.5 (3.0, 8.1)	0.40
MDS-UPDRS III, median (IQR)	25.0 (17.0, 35.0)	26.0 (17.0, 35.0)	25.0 (17.0, 34.0)	0.84	25.00 (17.00, 35.00)	28.0 (17.0, 36.5)	0.26

H&Y Stage < 3	401 (89.1%)	314 (89.7%)	87 (87%)	0.76			0.66
BAI Score, median (IQR)	7.0 (4.0, 13.0)	7.0 (4.0, 13.0)	7.0 (3.0, 14.0)	0.70	7.0 (3.0, 14.0)	7.0 (4.0, 12.0)	0.73
BDI Score, median (IQR)	7.0 (4.0, 11.0)	7.0 (4.0, 11.0)	6.0 (3.0, 11.5)	0.47	7.0 (4.0, 11.0)	5.5 (2.0, 11.0)	0.28
MoCA score, mean (SD)	26.3 (3.2)	26.2 (3.1)	26.5 (3.5)	0.46	26.2 (3.2)	26.8 (2.7)	0.26

OH: orthostatic hypotension, HS: high school, ABC: anti-cholinergic burden, LEDD: Levodopa Equivalent Daily Dose, MDS-UPDRS III: Movement Disorder Society Unified Parkinson's Disease Rating Scale, H&Y: Hoehn and Yahr, BAI: Beck Anxiety Inventory, BDI: Beck Depression Inventory, MoCA: Montreal Cognitive Assessment.

Figure 1. Effect of medications on the association between orthostatic hypotension and daytime sleepiness in Parkinson's disease

10. References

1.   Moreno-López C, Santamaría J, Salamero M, et al. Excessive daytime sleepiness in multiple system atrophy (SLEEMSA study). Arch Neurol. 2011 Feb;68(2):223-30.
2.   Gulyani S, Salas R, Mari Z, Choi S, Mahajan A, Gamaldo C. Evaluating and Managing Sleep Disorders in the Parkinson's Disease Clinic. Basal Ganglia. 2016 Aug;6(3):165-72.
3.   Merola A, Romagnolo A, Rosso M, et al. Orthostatic hypotension in Parkinson's disease: Does it matter if asymptomatic? Parkinsonism Relat Disord. 2016 Dec;33:65-71.
4.   Riley DE, Espay AJ. Cognitive fluctuations in Parkinson's disease dementia: blood pressure lability as an underlying mechanism. J Clin Mov Disord. 2018;5:1.
5.   Sturchio A, Marsili L, Vizcarra JA, et al. Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP). Front Aging Neurosci. 2020;12:553635.
6.   Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2015 Oct;30(12):1591-601.
7.   Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec;14(6):540-5.
8.   Högl B, Arnulf I, Comella C, et al. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Movement disorders : official journal of the Movement Disorder Society. 2010 Dec 15;25(16):2704-16.
9.   Shaw BH, Garland EM, Black BK, et al. Optimal diagnostic thresholds for diagnosis of orthostatic hypotension with a 'sit-to-stand test'. J Hypertens. 2017 May;35(5):1019-25.
10.   Palma JA, Kaufmann H. Orthostatic Hypotension in Parkinson Disease. Clin Geriatr Med. 2020 Feb;36(1):53-67.
11.   Norcliffe-Kaufmann L, Kaufmann H, Palma JA, et al. Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Ann Neurol. 2018 Mar;83(3):522-31.
12.   Nawaz H, Sargent L, Quilon H, et al. Anticholinergic Medication Burden in Parkinson's Disease Outpatients. J Parkinsons Dis. 2022;12(2):599-606.
13.   Jost ST, Kaldenbach MA, Antonini A, et al. Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals. Movement disorders : official journal of the Movement Disorder Society. 2023 Jul;38(7):1236-52.
14.   Simuni T, Caspell-Garcia C, Coffey C, et al. Correlates of excessive daytime sleepiness in de novo Parkinson's disease: A case control study. Movement disorders : official journal of the Movement Disorder Society. 2015 Sep;30(10):1371-81.
15.   Broderick J, Brott T, Kothari R, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998 Feb;29(2):415-21.
16.   Idiaquez J, Roman GC. Autonomic dysfunction in neurodegenerative dementias. J Neurol Sci. 2011 Jun 15;305(1-2):22-7.
17.   Seidel K, Mahlke J, Siswanto S, et al. The brainstem pathologies of Parkinson's disease and dementia with Lewy bodies. Brain Pathol. 2015 Mar;25(2):121-35.
18.   Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculopontine nucleus in Parkinson's disease. Ann Neurol. 1989 Jul;26(1):41-6.
19.   Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2009 Aug 15;24(11):1641-9.
20.   Knie B, Mitra MT, Logishetty K, Chaudhuri KR. Excessive daytime sleepiness in patients with Parkinson's disease. CNS Drugs. 2011 Mar;25(3):203-12.
21.   Ruiz Barrio I, Miki Y, Jaunmuktane ZT, Warner T, De Pablo-Fernandez E. Association Between Orthostatic Hypotension and Dementia in Patients With Parkinson Disease and Multiple System Atrophy. Neurology. 2023 Mar 7;100(10):e998-e1008.

22.   Pilleri M, Facchini S, Gasparoli E, et al. Cognitive and MRI correlates of orthostatic hypotension in Parkinson's disease. J Neurol. 2013 Jan;260(1):253-9.

23.   Seemiller J, Morrow C, Hinkle JT, et al. Impact of Acute Dopamine Replacement on Cognitive Function in Parkinson's Disease. Mov Disord Clin Pract. 2024 May;11(5):534-42.

24.   Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017 Aug;264(8):1567-82.

Subpopulation	N		Adjusted RC (95% CI)
Anticholinergic use	104

 | 4.15 (2.13, 6.18) |
| LEDD ≤750 mg | 209 | | 1.87 (0.48, 3.25) |
| Anticholinergic use & LEDD ≤750 mg | 53 | | 6.35 (2.84, 9.87) |